Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sasha A Philbert has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being processed by 1 distinct examiner and is located within 1 distinct art unit. Such a centralized prosecution profile suggests that the current patent efforts are focused on a specific pharmaceutical innovation. Since the applicant is only working within 1 distinct art unit, the procedural landscape for their application is relatively straightforward.
Pierre Paul Eleniste is the busiest examiner for this portfolio, managing 1 pending office action. This single action constitutes the total pending workload for the applicant. With only 1 distinct examiner involved, the outcome of the current filing depends entirely on the judgment of this one official. The data shows no other examiners or art units, meaning the applicant cannot compare this examiner's feedback against other internal benchmarks in the Biotechnology & Pharmaceuticals sector. Consequently, a thorough understanding of this examiner's past decisions is essential for a successful prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18136797 | TREATMENT OF BRAIN COPPER DISORDERS | ELENISTE, PIERRE PAUL | 60d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18136797 | TREATMENT OF BRAIN COPPER DISORDERS | ELENISTE, PIERRE PAUL | 1622 | §103Other | Final Rejection | 60d overdue | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSasha A Philbert has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Pierre Paul Eleniste has the most, with 1 of Sasha A Philbert's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
